Skip to content
Browse our latest resources
Keep up with our latest news.
Learn more about our science.
Insights from our leadership team
Downloadable, infographics and more.
The Crestone Study
Elevation Oncology Announces Clinical Cancer Research Publication Highlighting the Specific Inhibition of HER3 by Seribantumab in Preclinical NRG1 Fusion Models
Filter by Quarter
November 30, 2022
Elevation Oncology to Participate at the JMP Securities Hematology and Oncology Summit
November 03, 2022
Elevation Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
August 04, 2022
Elevation Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
July 28, 2022
Elevation Oncology Secures $50 Million Loan Facility with K2 HealthVentures
July 28, 2022
Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group
May 26, 2022
Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022
Track our progress
Check back often for our latest insights, or sign up for our mailing list to receive the have the latest news and publications from Elevation Oncology delivered to your inbox.
This field is for validation purposes and should be left unchanged.